Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 4Genitourinary 4Gynecologic 3Head & Neck 2Breast 2Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Electroporation × Breast × Clear all
NCT02531425 2023-05-15

TNBC

OncoSec Medical Incorporated

Phase 1 Completed
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03240224 2019-01-25

Bioinformation Therapy for Breast Cancer

Fuda Cancer Hospital, Guangzhou

Phase 2/3 Completed
120 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡